INHIBITION OF SLC4A4 IN THE TREATMENT OF CANCER Flanders Institute for Biotechnology
The invention relates to the application of inhibition of SLC4A4 (Solute Carrier Family 4 member 4) in the treatment of cancer. This either as monotherapy (such as for treating cancer refractive or poorly responding to immunotherapy) or as combination therapy in conjunction with an immunotherapeutic compound (such as for treating cancers poorly responding or refractive to immunotherapy). In particular, inhibition of SLC4A4 is capable of restoring response to immunotherapy such as immune checkpoint inhibitor therapy.